Blog

$Gertjan Rasschaert: Botbal in refractory pMMR/MSS mCRC: a phase 1 trial by Andrea J. Bullock et al.$

Jun 15, 2024, 09:25

Gertjan Rasschaert: Botbal in refractory pMMR/MSS mCRC: a phase 1 trial by Andrea J. Bullock et al.

Gertjan Rasschaert, Medical Doctor, Consultant Gastrointestinal Oncology and Gastroenterology at

“Botbal in refractory pMMR/MSS mCRC: a phase 1 trial

In the response-evaluable population (n = 101), ORR was 17% (95% CI 10–26%), DCR 61% (95% CI, 51–71%) and median PFS 3.5 months (95% CI, 2.7–4.1 months), at a median FU of 10.3 months.

A randomized phase 2 study of this combination is underway to confirm the comparative safety and efficacy of the BOT and BAL combination. With enthusiast participation of DIO UZ Leuven !

g is cooking in the age group of 20-49 years. Also the exact reason why just lowering the screening age to 45 years won’t suffice.”

Read further.
Source: Gertjan Rasschaert/X

cancer cancer treatment Gastroenterology Gastrointestinal Oncology Gertjan Rasschaert mCRC medical oncology MSS OncoDaily Oncology oncology research Phase 1 trial pMMR Research UZ Leuven

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage